Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer
|ClinicalTrials.gov Identifier: NCT00740636|
Recruitment Status : Completed
First Posted : August 25, 2008
Results First Posted : February 1, 2016
Last Update Posted : August 1, 2016
The purpose of this study is to determine whether treatment with temozolomide will shrink small cell lung cancer tumors. Temozolomide is an oral chemotherapy drug that is currently used to treat brain cancer and melanoma.
As part of this study, we will be doing additional tests that may help us understand how temozolomide works. First, if there is a tumor sample from a biopsy done in the past, it will be analyzed for an abnormal gene that may be present in lung cancer. Before starting temozolomide, a research blood test will be done to look for the same abnormal gene we are looking for in your tumor sample. Also, before starting temozolomide and every time you have a repeat CT scan, a research blood test will be done to analyze the number of tumor cells in your bloodstream.
|Condition or disease||Intervention/treatment||Phase|
|Lung Cancer||Drug: Temozolomide||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||92 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Study of Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer|
|Study Start Date :||August 2008|
|Primary Completion Date :||February 2013|
|Study Completion Date :||February 2013|
Experimental: 75 mg/m2/day Temozolomide
75 mg/m2/day Temozolomide for 21 days (7 days off treatment). 28 day cycles.
Temozolomide will be administered orally once per day on days 1 through 5 of a 28 day cycle. The dose will be 75 mg/m2/day.
Experimental: 200 mg/m2/day Temozolomide
200 mg/m2/day Temozolomide for 5 days (23 days off treatment). 28 day cycles.
Temozolomide will be administered orally once per day on days 1 through 5 of a 28 day cycle. The dose will be 200mg/m2/day.
- The Objective Overall Response [ Time Frame: 2 years ]
The objective response is defined as all complete responses and partial responses based on the modified RECIST.Complete Response (CR): Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00740636
|United States, New Jersey|
|Memoral Sloan Kettering Cancer Center|
|Basking Ridge, New Jersey, United States|
|United States, New York|
|Memorial Sloan-Kettering Cancer Center at Commack|
|Commack, New York, United States, 11725|
|Memorial Sloan-Kettering Cancer Center|
|New York, New York, United States, 10065|
|Memorial Sloan-Kettering Cancer Center at Mercy Medical Center|
|Rockville Centre, New York, United States, 11570|
|Memoral Sloan Kettering Cancer Center@Phelps|
|Sleepy Hollow, New York, United States|
|Principal Investigator:||Maria Pietanza, MD||Memorial Sloan Kettering Cancer Center|